The present invention provides a highly palatable colon cleansing formulation that utilizes a low chloride electrolyte-replenishing base solution. When formulated with polyethylene glycol and a selected sugar alcohol, the formulation offers the advantages of superior palatability without undesirable concomitant side effects or a decrease in cleansing efficacy.

Combination of dry extract of Rhodiola, dry extract of Trubulus terrestris, dry extract of Undaria pinnatifida, Moringa oleifera, folic acid and vitamin B12 in the form of food supplement for mitigating woman's disorders caused by ageing.

Alternative methods for sealing pouch materials, for example, using radio frequency (RF) sealing techniques, and oral pouched products formed according to those methods are provided. Some pouched products may include an outer water-permeable pouch defining a cavity having a composition situated in the cavity, wherein the outer water-permeable pouch comprises a fleece material, the fleece material comprising a plurality of fibers and an RF sealable material. In some embodiments, methods of RF sealing pouch materials may include providing one or more fleece materials having a RF sealable material and sealing the one or more fleece materials using radio frequency energy to form a RF sealed pouched product.

Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Compositions for intravenous infusion of istaroxime, or a metabolite of istaroxime, in human patients suffering from heart failure are disclosed. Likewise, methods for extended infusion of istaroxime or its metabolites in individuals with heart failure are disclosed. In particular, some methods disclosed herein include the infusion of istaroxime, or a metabolite thereof, for a period of time that is greater than six hours in order to improve cardiac relaxation without triggering arrhythmogenic events in an individual suffering from heart failure. Other methods include administration of istaroxime until certain plasma concentration thresholds of istaroxime metabolites are achieved. Also disclosed are istaroxime metabolites with selective SERCA2a activation.

The disclosure provides an effervescent composition adapted for oral use, the composition including an effervescent material; one or more fillers in a total amount of at least about 30% by weight, the one or more fillers including at least one sugar alcohol; at least one active ingredient; and optionally, a lipid in an amount of at least about 20% by weight. Melting effervescent compositions are also provided, which include the lipid.

Provided herewith is a device having one sachet or more than one nested sachet with the largest sachet made of, e.g., a non-dissolvable, porous, wettable and non-toxic material. The sachets are filled with a desired combination of medications and excipients to provide sustained dosing, blood levels and effects of the said combination of medications. The sachets can be arranged in such a configuration to be suitable for placement in the oral/buccal cavity with comfort and to deliver, e.g.. continuous or on-demand release of the desired medications for both transmucosal and gastrointestinal absorption. Also provided are containers for such devices.

A pouched product adapted for release of a releasable component therefrom is provided herein. The pouched product can include a water-permeable fabric pouch formed so as to define a cavity therein, and a composition contained within the cavity of the water-permeable fabric pouch, the composition including one or more releasable components that are released from the composition under mouth conditions and that are capable of movement through the water-permeable fabric pouch. The composition includes nicotine and at least one particulate non-tobacco material. The pouched product also includes at least one capsule contained within the cavity of the water-permeable fabric pouch, the capsule having a capsule wall surrounding an inner payload comprising at least one botanical.

The present invention discloses an extended release oral liquid pharmaceutical composition comprising eslicarbazepine or its pharmaceutically acceptable esters, salts, solvates, polymorphs, enantiomers or mixtures thereof in a pharmaceutically acceptable carrier. The extended release liquid compositions are in the form of ready-to-use liquid compositions or reconstituted liquid compositions. It also relates to processes for the preparation of said extended release liquid compositions. The prior art discloses immediate release oral liquid dosage form. The prepared novel test formulations exhibited desired pharmaceutical technical attributes.

A method for preventing unwanted side effects associated with the administration stimulant laxative such as bisacodyl or sodium picosulphate by orally administering sodium chloride to the patient is disclosed. Said side effects include hyponatraemia, hypokalemia, unwanted fluctuations in blood pressure, hypotension and renal failure. In certain embodiments, the sodium chloride is administered in the form of tablets during the two hours period following the administration of the stimulant laxative. This method is particularly useful in preparing patients for a colonoscopy.